Acadia enters DAYBUE STIX distribution agreement in Japan
Released
Released
Announcement PDF
1 of 2
Neuren (NEU) – ASX Announcement 17 November 2026
Acadia enters exclusive distribution agreement for DAYBUE® STIX in Japan
Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU)’s exclusive global partner for trofinetide,
Acadia Pharmaceuticals (Nasdaq: ACAD), has announced that it has entered into an exclusive
distribution agreement with KYORIN Pharmaceutical Co., Ltd. (TSE: 4569), for the commercialization of
DAYBUE®
STIX in Japan. Acadia’s full announcement is available in the Investors section of the Acadia
website www.acadia.com.
Acadia recently completed the Phase 3 study of trofinetide in Rett syndrome in Japan, with results
consistent with the LAVENDERTM
Phase 3 study and supportive of a planned regulatory filing.
Neuren CEO Jon Pilcher commented: “We are pleased to see our partner Acadia making progress in
preparation for the anticipated regulatory filing in Japan in 2027, with a potential launch in 2028 subject
to regulatory approval.”
Under Neuren’s licence agreement with Acadia, for Japan, Neuren is entitled to receive US$15 million
following first commercial sale, potential sales milestone payments of up to US$110 million on
achievement of escalating annual net sales thresholds, and tiered royalties ranging from mid-teens to
low-twenties percentage of net sales.
Click here to view this announcement on our Investor Hub.
About Neuren
Neuren Pharmaceuticals is developing new drug therapies to treat multiple serious neurological
disorders caused by genetic abnormalities or brain injury, that have no or limited approved treatment
options. Neuren’s therapies target the critical role of Insulin-like growth factor 1 (IGF-1) in the brain,
using orally administered analogs of naturally occurring peptides.
DAYBUE® (trofinetide) oral solution and DAYBUE STIX (trofinetide) powder are approved for the
treatment of Rett syndrome by the US Food and Drug Administration (FDA). The oral solution is also
approved by the European Medicines Agency, Health Canada and the Ministry of Health in Israel.
Neurenhasgrantedan exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development
and commercialisation of trofinetide.
Neuren’s investigative drug candidate, NNZ-2591 (ercanetide), is in clinical development as an oral
solution treatmentfor multiple neurodevelopmental disorders, including Phelan-McDermid syndrome,
Pitt Hopkins syndrome and Angelman syndrome. Each of these programs has been granted “orphan
drug” designation in the United States and the European Union as well as Fast Track and Rare Pediatric
Disease designations from the FDA. NNZ-2591 has also been granted orphan drug designation for the
treatmentof hypoxicischemic encephalopathy(HIE),aseriousconditioncausedby brain injurybefore or
shortly after birth.
2 of 2
Currently, Neuren is conducting a Phase 3, randomized, double-blind, placebo-controlled clinical trial
(“Koala”) evaluating the safety and efficacy of NNZ-2591 in children aged 3 to 12 years with Phelan-
McDermid syndrome and a 52-week open-label extension study.
https://neurenpharma.com/link/PmEzMP
Investor contact:
Jon Pilcher, CEO & Managing Director
+61 438 422 271
investorrelations@neurenpharma.com
Media Contact:
Monsoon Communications
Rudi Michelson
rudim@monsoon.com.au
ASX Listing Rules information
This announcement was authorized to be given to the ASX by the Board of Neuren Pharmaceuticals
Limited, Suite 1.01, 117 Camberwell Road, Hawthorn East, VIC 3123
Forward-looking Statements
This announcementcontainsforward-lookingstatementsthataresubjectto risksand uncertainties.Such
statements involve known and unknown risks and important factors that may cause the actual results,
performance or achievements of Neuren to be materially different from the statements in this
announcement.
Investor Hub
Share your feedback
Discover